Form 6-K Vale S.A. For: Dec 09
United States
Securities and Exchange Commission
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For the month of
December 2016
Vale S.A.
Avenida das Américas, No. 700 Bloco 8, Sala 218
22640-100 Rio de Janeiro, RJ, Brazil
(Address of principal executive office)
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)
(Check One) Form 20-F x Form 40-F o
(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1))
(Check One) Yes o No x
(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7))
(Check One) Yes o No x
(Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)
(Check One) Yes o No x
(If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b). 82- .)
|
|
Vale obtains operating license for the S11D project
Rio de Janeiro, December 9, 2016 Vale S.A. (Vale) informs that it obtained the operating license (LO) for the S11D mine and plant, issued by the Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais Renováveis (IBAMA).
The S11D mine and plant achieved physical progress of 96% as of October 30th, 2016 and the hot commissioning is progressing well. A 110 wagon train was loaded with aproximately 10,000 tons of product. S11D start-up is expected for the end of 2016 with the first commercial shipment in January 2017.
The LO for the S11D mine and plant is an important milestone to consolidate Vales position as the lowest C1 cash cost producer in the industry.
For further information, please contact:
+55-21-3485-3900
Andre Figueiredo: [email protected]
Carla Albano Miller: [email protected]
Fernando Mascarenhas: [email protected]
Andrea Gutman: [email protected]
Bruno Siqueira: [email protected]
Claudia Rodrigues: [email protected]
Denise Caruncho: [email protected]
Mariano Szachtman: [email protected]
Renata Capanema: [email protected]
This press release may include statements that present Vales expectations about future events or results. All statements, when based upon expectations about the future, involve various risks and uncertainties. Vale cannot guarantee that such statements will prove correct. These risks and uncertainties include factors related to the following: (a) the countries where we operate, especially Brazil and Canada; (b) the global economy; (c) the capital markets; (d) the mining and metals prices and their dependence on global industrial production, which is cyclical by nature; and (e) global competition in the markets in which Vale operates. To obtain further information on factors that may lead to results different from those forecast by Vale, please consult the reports Vale files with the U.S. Securities and Exchange Commission (SEC), the Brazilian Comissão de Valores Mobiliários (CVM), and the French Autorité des Marchés Financiers (AMF), and in particular the factors discussed under Forward-Looking Statements and Risk Factors in Vales annual report on Form 20-F.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Vale S.A. | |
|
(Registrant) | |
|
| |
|
By: |
/s/ André Figueiredo |
Date: December 09, 2016 |
|
Director of Investor Relations |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Reiterates Outperform Rating on Vale S.A. (VALE3:BZ) (VALE)
- AGILITI ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of AGTI and Encourages Investors to Contact the Firm
- Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!